<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="393">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00984620</url>
  </required_header>
  <id_info>
    <org_study_id>1220.40</org_study_id>
    <secondary_id>2009-012579-90</secondary_id>
    <nct_id>NCT00984620</nct_id>
  </id_info>
  <brief_title>Short Term Treatment With BI 201335, Peginterferon-alpha 2a and Ribavirin in Hepatitis c Virus Genotype-1 Treatment-naïve Patients (SILEN-C3)</brief_title>
  <official_title>Antiviral Effect and Safety of Once Daily BI 201335 NA in Hepatitis C Virus Genotype 1 Infected Treatment-naive Patients for 12 or 24 Weeks as Combination Therapy With Pegylated Interferon-alpha 2a and Ribavirin (Randomised, Open Label, Phase II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Austria: Federal Office for Safety in Health Care</authority>
    <authority>Canada: Health Canada</authority>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Romania: National Medicines Agency</authority>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the antiviral efficacy and safety of a 12-week with a 24-week treatment of BI
      201335 at a dose of 120 mg once daily, with a 24-week background of pegylated
      interferon-alpha 2a (PegIFN) plus ribavirin (RBV), in treatment-naïve patients infected with
      hepatitis C virus (HCV) genotype 1
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Virological Response at Week 28 (W28VR)</measure>
    <time_frame>28 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Virological response at Week 28: The patients who reached plasma hepatitis C virus ribonucleic acid (HCV RNA) level below the lower limit of detection (BLD) at Week 28.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rapid Virological Response at Week 4 (RVR)</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Rapid virological response at week 4 (RVR): The patients who reached plasma hepatitis C virus ribonucleic acid (HCV RNA) level below the lower limit of detection (BLD) at week 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virological Response at Week 24 (W24VR)</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>virological response at week 24 (W24VR): The patients who reached plasma hepatitis C virus ribonucleic acid (HCV RNA) level below the lower limit of detection (BLD) at week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virological Response at Week 36 (W36VR)</measure>
    <time_frame>36 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Virological response at week 36 (W36VR): the patients who reached plasma hepatitis C virus ribonucleic acid (HCV RNA) level below the lower limit of detection (BLD) at week 36.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End of Treatment Response (ETR)</measure>
    <time_frame>up to 48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>End of Treatment Response (ETR): The patients who reached plasma hepatitis C virus ribonucleic acid (HCV RNA) level below the lower limit of detection (BLD) at end of all therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained Virological Response (SVR24) at 24 Weeks After Completion of All Therapy</measure>
    <time_frame>72 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Sustained Virological Response (SVR24) at 24 weeks: The patients who reached plasma Hepatitis C virus Ribonucleic acid (HCV RNA) level below the lower limit of detection (BLD) at 24 weeks after completion of all Hepatitis C virus (HCV) therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral Load (HCV RNA) at All Visits During Treatment and Follow-up</measure>
    <time_frame>From baseline to 72 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Viral load of Hepatitis C virus Ribonucleic acid (HCV RNA) at all visits during treatment (TRT) and follow-up, ie. change from baseline viral load at all visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach a Plasma HCV RNA Level BLD While on Treatment</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time to reach a plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) level below the lower limit of detection (BLD) while on treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Test Abnormalities and Study Medication Tolerabilities</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Participants with possible clinically significant laboratory test abnormalities observed in functional groups: Haematology, Coagulation, Electrolytes, Enzymes, Substrates and Differentials, automatic.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Relevant Abnormalities Vital Signs, and Physical Examination</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>No number of participants with clinically relevant abnormalities in vital signs and physical examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (1)</measure>
    <time_frame>baseline and 48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline (CFB) in Red blood cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (2)</measure>
    <time_frame>baseline and 48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline (CFB) in haematocrit and Eosinophils.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (3)</measure>
    <time_frame>baseline and 48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline (CFB) in Platelets and white blood cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (4)</measure>
    <time_frame>baseline and 48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline (CFB) in Sodium, Bicarbonate, Cholesterol total, Triglyceride, and Glucose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (5)</measure>
    <time_frame>baseline and 48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline (CFB) in AST/GOT, ALT/GPT, Alka. phosphatase, GGT, Creatine kinase, Lipase, and Amylase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (6)</measure>
    <time_frame>baseline and 48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline (CFB) in PT-INR (ratio).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>short arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients to receive BI201335 with PegIFN/RBV for 12 wks followed by 12 weeks PegIFN/RBV with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of BI 201335 NA 3 days after first administration of PegIFN/RBV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>long arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients to receive BI201335 with PegIFN/RBV for 24 wks with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of BI 201335 NA 3 days after first administration of PegIFN/RBV)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 201335</intervention_name>
    <description>BI 201335</description>
    <arm_group_label>long arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 201335</intervention_name>
    <description>BI 201335</description>
    <arm_group_label>short arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated Interferon-alpha (IFN)</intervention_name>
    <description>Pegylated Interferon-alpha</description>
    <arm_group_label>short arm</arm_group_label>
    <arm_group_label>long arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin (RBV)</intervention_name>
    <description>Ribavirin (RBV)</description>
    <arm_group_label>short arm</arm_group_label>
    <arm_group_label>long arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Chronic hepatitis C infection of genotype 1

          2. Therapy-naïve to interferon, pegylated interferon, and ribavirin

          3. HCV viral load &gt; 100.000 IU/ml at screening

          4. Liver biopsy or fibroscan within two years prior to screening that provides evidence
             of any degree of fibrosis or cirrhosis

          5. Normal retinal finding on fundoscopy within 6 months prior to Day 1

          6. Age 18 to 70 years

        Exclusion criteria:

          1. HCV of mixed genotype (1/2, 1/3, and 1/4) .

          2. Patients who have been previously treated with at least one dose of any protease
             inhibitor

          3. Evidence of liver disease due to causes other than chronic HCV infection

          4. Positive for HIV-1 or HIV-2 antibodies

          5. Hepatitis B virus (HBV) infection

          6. Decompensated liver disease, or history of decompensated liver disease

          7. Active malignancy or history of malignancy within the last 5 years

          8. History of alcohol or drug abuse (except cannabis) within the past 12 months.

          9. Body Mass Index &lt; 18 or &gt; 35 kg/m2.

         10. Usage of any investigational drugs within 30 days prior to enrolment

         11. Alpha fetoprotein value &gt;100ng/mL at screening;

         12. Total bilirubin &gt; 1.5 x ULN with ratio of direct/indirect &gt; 1.

         13. ALT or AST level &gt; 10 x ULN
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1220.40.002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tulepo</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.4303 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.4301 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.1004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.1001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.1002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.1003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.1005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.3303A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clichy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.3305A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.3301A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.3306A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.3302A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.3304A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rennes Cedex 09</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.4902 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.4909 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.4906 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.4908 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.4904 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.4905 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.4001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.4002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.4003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Romania</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Taiwan</country>
  </removed_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
  </link>
  <verification_date>August 2015</verification_date>
  <lastchanged_date>August 7, 2015</lastchanged_date>
  <firstreceived_date>September 24, 2009</firstreceived_date>
  <firstreceived_results_date>July 3, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results are available for this study                                           -->
</clinical_study>
